Affordable Prescriptions for Patients Act of 2023
USA118th CongressS-150| Senate
| Updated: 7/15/2024
John Cornyn
Republican Senator
Texas
Cosponsors (8)
Judiciary Committee
- Introduced
- In Committee
- On Floor
- Passed Chamber
- Enacted
Affordable Prescriptions for Patients Act of 2023 This bill limits in certain instances the number of patents that a reference biological product manufacturer can assert in a patent infringement lawsuit against a company seeking to sell a biosimilar version. Specifically, if the biosimilar manufacturer completes certain actions as part of an abbreviated pathway to get market approval, the bill limits, subject to exceptions and waivers, the number of certain types of patents that the reference product manufacturer may assert, such as patents filed more than four years after the reference product received market approval.
Suggested Questions
Get AI-generated questions to help you understand this bill better
Timeline
Introduced in Senate
Read twice and referred to the Committee on the Judiciary.
Committee on the Judiciary. Ordered to be reported without amendment favorably.
Committee on the Judiciary. Reported by Senator Durbin without amendment. Without written report.
Placed on Senate Legislative Calendar under General Orders. Calendar No. 22.
Passed/agreed to in Senate: Passed Senate with an amendment by Unanimous Consent.
Passed Senate with an amendment by Unanimous Consent. (text of amendment in the nature of a substitute: CR S4537-4538)
Measure laid before Senate by unanimous consent. (consideration: CR S4537-4538)
Message on Senate action sent to the House.
Received in the House.
Held at the desk.
Health
Administrative remediesCivil actions and liabilityCompetition and antitrustConsumer affairsDrug safety, medical device, and laboratory regulationFederal Trade Commission (FTC)Health care costs and insuranceInflation and pricesIntellectual propertyJudicial review and appealsManufacturingPrescription drugs
Affordable Prescriptions for Patients Act of 2023
USA118th CongressS-150| Senate
| Updated: 7/15/2024
Affordable Prescriptions for Patients Act of 2023 This bill limits in certain instances the number of patents that a reference biological product manufacturer can assert in a patent infringement lawsuit against a company seeking to sell a biosimilar version. Specifically, if the biosimilar manufacturer completes certain actions as part of an abbreviated pathway to get market approval, the bill limits, subject to exceptions and waivers, the number of certain types of patents that the reference product manufacturer may assert, such as patents filed more than four years after the reference product received market approval.
Suggested Questions
Get AI-generated questions to help you understand this bill better
Timeline
Introduced in Senate
Read twice and referred to the Committee on the Judiciary.
Committee on the Judiciary. Ordered to be reported without amendment favorably.
Committee on the Judiciary. Reported by Senator Durbin without amendment. Without written report.
Placed on Senate Legislative Calendar under General Orders. Calendar No. 22.
Passed/agreed to in Senate: Passed Senate with an amendment by Unanimous Consent.
Passed Senate with an amendment by Unanimous Consent. (text of amendment in the nature of a substitute: CR S4537-4538)
Measure laid before Senate by unanimous consent. (consideration: CR S4537-4538)
Message on Senate action sent to the House.
Received in the House.
Held at the desk.
John Cornyn
Republican Senator
Texas
Cosponsors (8)
Judiciary Committee
Health
- Introduced
- In Committee
- On Floor
- Passed Chamber
- Enacted
Administrative remediesCivil actions and liabilityCompetition and antitrustConsumer affairsDrug safety, medical device, and laboratory regulationFederal Trade Commission (FTC)Health care costs and insuranceInflation and pricesIntellectual propertyJudicial review and appealsManufacturingPrescription drugs